Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  156,787 results for ""LACTAMS""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

  • Authors : Lin JJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Horan JC

Subjects: Aminopyridines*/Aminopyridines*/Aminopyridines*/therapeutic use ; Aminopyridines*/Aminopyridines*/Aminopyridines*/pharmacology ; Anaplastic Lymphoma Kinase*/Anaplastic Lymphoma Kinase*/Anaplastic Lymphoma Kinase*/antagonists & inhibitors

  • Source: Cancer discovery [Cancer Discov] 2024 Dec 02; Vol. 14 (12), pp. 2367-2386.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report.

  • Authors : Kunimasa K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.; Miyazaki A

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: Thoracic cancer [Thorac Cancer] 2024 Dec; Vol. 15 (36), pp. 2570-2574. Date of Electronic Publication: 2024 Nov 11.Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.

  • Authors : Garcia C; Department of Medicine, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY. Electronic address: .; Abrahami D

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Clinical lung cancer [Clin Lung Cancer] 2024 Nov; Vol. 25 (7), pp. 634-642. Date of Electronic Publication: 2024 Aug 13.Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer.

  • Authors : Sampson J; Astbury Centre for Structural Molecular Biology and School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK. .; Ju HM

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy

  • Source: Cell death & disease [Cell Death Dis] 2024 Dec 18; Vol. 15 (12), pp. 912. Date of Electronic Publication: 2024 Dec 18.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care.

Subjects: Dyslipidemias*/Dyslipidemias*/Dyslipidemias*/epidemiology ; Weight Gain*/Weight Gain*/Weight Gain*/drug effects ; Lactams*

  • Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Dec; Vol. 198, pp. 108034. Date of Electronic Publication: 2024 Nov 19.Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Exploring the binding characteristics between lorlatinib and human alpha-1-acid glycoprotein: Multispectral and molecular modeling techniques.

  • Authors : Sui HY; College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China.; Chen D

Subjects: Aminopyridines*/Aminopyridines*/Aminopyridines*/chemistry ; Aminopyridines*/Aminopyridines*/Aminopyridines*/metabolism ; Lactams*/Lactams*/Lactams*/chemistry

  • Source: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2025 Feb 05; Vol. 326, pp. 125197. Date of Electronic Publication: Publisher: Elsevier Country of Publication: England NLM ID: 9602533 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3557

Record details

Read More Add to Saved list
×
Academic Journal

Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.

  • Authors : Igawa Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: .; Yoshida T

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Aminopyridines*/Aminopyridines*/Aminopyridines*/adverse effects ; Aminopyridines*/Aminopyridines*/Aminopyridines*/administration & dosage

  • Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Oct; Vol. 196, pp. 107954. Date of Electronic Publication: 2024 Sep 12.Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer.

  • Authors : Guaitoli G; Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena.; Martinelli E

Subjects: Lactams*/Lactams*/Lactams*/therapeutic use ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology

  • Source: Anti-cancer drugs [Anticancer Drugs] 2024 Oct 01; Vol. 35 (9), pp. 867-871. Date of Electronic Publication: 2024 Jul 09.Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Editorial & Opinion

The case for publicly funding lorlatinib.

  • Authors : Ashton JC; Department of Pharmacology and Toxicology, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.

Subjects: Lactams*/Lactams*/Lactams*/economics ; Pyrazoles*/Pyrazoles*/Pyrazoles*/economics ; Pyrazoles*/Pyrazoles*/Pyrazoles*/therapeutic use

  • Source: The New Zealand medical journal [N Z Med J] 2024 Aug 23; Vol. 137 (1601), pp. 77-79. Date of Electronic Publication: 2024 Aug 23.Publisher: Pasifika Medical Association Group Country of Publication: New Zealand NLM ID: 0401067 Publication Model: Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Microwave-Assisted Atom Transfer Radical Cyclization in the Synthesis of 3,3-Dichloro-γ- and δ-Lactams from N -Alkenyl-Tethered Trichloroacetamides Catalyzed by RuCl 2 (PPh 3 ) 3 and Their Cytotoxic Evaluation.

  • Authors : Diaba F; Laboratori de Química Orgànica, Facultat de Farmàcia i Ciències de l'Alimentació, IBUB, Universitat de Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.; Sandor AG

Subjects: Lactams*/Lactams*/Lactams*/chemistry ; Lactams*/Lactams*/Lactams*/chemical synthesis ; Lactams*/Lactams*/Lactams*/pharmacology

  • Source: Molecules (Basel, Switzerland) [Molecules] 2024 Apr 28; Vol. 29 (9). Date of Electronic Publication: 2024 Apr 28.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

Read More Add to Saved list
×
  • 1-10 of  156,787 results for ""LACTAMS""